The infection of recombinant adenovirus expressing wild-type p53 (Ad-p53) to lung cancer cells that harbor mutant p53 genes improves their response to cis-diamminedichloroplatinum(II). In this study, we tested whether this improvement in response is also seen in wild-type p53 (wt-p53)-containing cancer cells and whether this phenomenon is universal with other commonly used chemotherapeutic agents, including etoposide, 7-ethyl-10-hydrocycamptothecin, paclitaxel, and docetaxel. Using a panel of 7 non-small cell lung cancer cell lines with wild-type (2) or abnormal (2 null, 3 point-mutated) p53, we examined in vitro cytotoxicity using a tetrazolium-based colorimetric assay (3-(4,5-diethylthiazoyl-2-yl)-2,5-diphenyltetrazolium bromide assay) and analyzed the combined effects of Ad-p53 and chemotherapeutic agents using the isobologram method. Ad-p53 and DNA-damaging agents (cis-diamminedichloroplatinum(II), etoposide, and 7-ethyl-10-hydrocycamptothecin) showed synergistic effects in six of seven cell lines but additive effects against a p53-mutated cell line. In contrast, Ad-p53 showed additive effects with the antitubulin agents (paclitaxel and docetaxel) in all four of the cell lines tested. Furthermore, we examined this synergistic interaction between Ad-p53 and DNA-damaging agents by flow cytometric analysis and DNA fragmentation analysis. Both analyses revealed that a sublethal dose of Ad-p53 augmented the apoptotic response induced by DNA-damaging agents in six of seven cell lines. Our results suggest that Ad-p53 may synergistically enhance the chemosensitivity of the majority of non-small cell lung cancers to DNA-damaging agents due to augmentation of apoptosis. Cancer Gene Therapy (2000) 7, 537-544
M olecular analysis has demonstrated that lung cancer cells accumulate a number of genetic alterations, including oncogenes and tumor suppressor genes, to develop an overt lung cancer. 1 Among these genetic alterations, the p53 gene is the most frequent target for non-small cell lung cancer (NSCLC) development, 2 and p53 mutations appear to be associated with a poor prognosis in NSCLC patients. 3 There is compelling evidence that wild-type p53 (wt-p53) plays important roles in modulating or mediating cell cycle control, apoptosis, or genomic stability. 4, 5 In cells expressing mutant p53 (mt-p53), these effects of wt-p53 are abrogated. As precise knowledge of the disrupted physiology in cancer cells increases, specific new therapeutic approaches such as gene therapy have been expected. 6 In vitro and in vivo studies have demonstrated increased resistance to cell death in p53-mutated cells after damage by DNA-damaging agents. [7] [8] [9] [10] This resistance is most likely due to the fact that cells without wt-p53 delay or are unable to initiate apoptosis. 7, 11, 12 In fact, administration of Ad-p53 with cis-diamminedichloroplatinum(II) (CDDP) induced tumor regression as well as apoptosis in p53-deleted human lung tumors that were grown as subcutaneous xenographs in nu/nu mice. 13 On the basis of these findings, gene therapy against p53-mutated NSCLC has started.
14 However, it is not known whether this effect holds for the whole spectrum of anti-cancer agents in lung cancer cells. Moreover, it remains unclear whether this approach can enhance the effect of anti-cancer agents in cancer cells with wt-p53.
In this study, we evaluated whether Ad-p53 could enhance the chemosensitivity of NSCLC cell lines to five anti-cancer agents in vitro; three of these agents are DNA-damaging agents, and the other two are antitubulin agents. The individual cytotoxicities of Ad-p53, AdLacZ, or anti-cancer agents were examined with the 3-(4,5-diethylthiazoyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and the combined effects on 50% cell growth inhibition (IC 50 ) values were analyzed by isobolograms. In addition, the interaction between Ad-p53 and anti-cancer agents was studied by flow cytometric analysis and DNA fragmentation analysis. We report here that the combined effects of Ad-p53 with DNAdamaging agents are synergistic regardless of the endogenous p53 status in the majority of NSCLCs, and that this synergism may be attributed to the augmentation of apoptosis.
MATERIALS AND METHODS

Cell lines
Seven NSCLC cell lines were used. A549 was obtained from the American Type Culture Collection (Manassas, Va) and maintained in Eagle's minimum essential medium. The remaining cell lines (H23, H226, H322, H358, H460, and H1299) were established at the National Cancer Institute (Bethesda, Md) and were kindly provided by Dr. Adi Gazder (University of Texas Southwestern Medical Center, Dallas, Tex). These cells were maintained in RPMI 1640 medium. All media were supplemented with 10% heat-inactivated fetal bovine sera.
Recombinant adenoviruses
The construction and generation of recombinant adenoviruses expressing wt-p53 (Ad-p53) and ␤-galactosidase (Ad-LacZ) have been described previously. 15 The multiplicity of infection (MOI) was defined as the ratio of the total number of plaque-forming units used in a particular infection to the total number of cancer cells to be infected.
Western blot analysis
After a 24-hour Ad-p53 infection of cancer cells, cell lysates were prepared, electrophoresed, and blotted as described previously. 15 Immunoblots were detected using the enhanced chemiluminescence system (Amersham, Little Chalfont, UK) according to the manufacturer's instructions and were exposed onto Amersham Hyperfilm. The primary monoclonal antibodies used were anti-human p53 pAb1801 and anti-human p21 EA10 (Oncogene Research Products, Cambridge, Mass).
Drugs
Docetaxel (Taxotere) was kindly provided by Rhone-Poulenc Rorer (Tokyo, Japan). 7-ethyl-10-hydrocycamptothecin (SN-38), which is an active metabolite of 7-ethyl-10-(4-[11-piperidyl]-1-piperidyl)-carbonyloxy-camptothecin, was provided by Yakult Honsha (Tokyo, Japan). CDDP, etoposide, and paclitaxel (Taxol) were provided by Bristol-Myers-Squibb (Tokyo, Japan).
MTT assay
Exponentially growing cells were harvested and resuspended to a final concentration of 1-8 ϫ 10 4 cells/mL in fresh medium. Cell suspensions (100 L) were dispensed into wells of 96-well tissue-culture plates. After incubation at 37°C for 24 hours, the solutions of the anti-cancer agents of various concentrations or adenoviruses of various MOIs were simultaneously added and subsequently incubated for 3 days. Cytotoxicity was determined using the MTT assay described previously. 16 
Isobologram analysis
The effect of combining an adenovirus and an anti-cancer agent on the concentration producing an IC 50 was analyzed using an improved isobologram method and a curve-fitting analysis described previously. 16 -19 Briefly, based on the doseresponse curves of an adenovirus and an anti-cancer agent, three isoeffect lines, (mode I, mode IIa, and mode IIb) were drawn. In mode I, when a particular dose of an adenovirus resulted in a reduction in the survival fraction, the additional dose of an anti-cancer agent to reach the 50% survival level was required by taking the increment in doses, starting from 0, which produced log survivals that added up to IC 50 (heteroaddition). In modes IIa and IIb, when a particular dose of an adenovirus (an anti-cancer agent) resulted in a reduction in the survival fraction, the additional dose of an anti-cancer agent (an adenovirus) to reach the 50% survival level was required by taking the increment in doses, starting from the point on the dose-response curve of the adenovirus (the anti-cancer agent) where the effect of the adenovirus (the anti-cancer agent) had ended; this produced log survivals that added up to IC 50 (isoaddition). The maximum space surrounded by the two isoeffect lines was defined as the envelope of additivity. It yielded a constant biological effect when the two agents were used in combination. When each data point from the combination experiment fell within the space of the envelope of additivity, the interaction was regarded as additive. When each point fell in the inner space of the envelope of additivity, the combination was considered synergistic. When each data point fell into the outer space, the interaction was regarded as subadditive.
Flow cytometric analysis
Mock (medium)-infected, Ad-LacZ-infected, and Ad-p53-infected cells that had been treated or untreated with anti-cancer agents for 72 hours were collected and washed twice with cold phosphate-buffered saline. Cells were resuspended in phosphate-buffered saline containing 50 g/mL propidium iodide, 0.2% Nonidet P-40, 0.1% sodium citrate, and 1 mg/mL ribonuclease and analyzed on FACScalibur flow cytometer (Becton Dickinson, Mountain View, Calif) for DNA content. Cell debris and fixation artifacts were gated out.
Detection of low-molecular weight DNA fragmentation DNA was isolated using a standard phenol-chloroform extraction procedure with slight modifications. 13 Samples that had been treated with ribonuclease A for 60 minutes were subjected to electrophoresis on a 1.5% agarose gel and visualized by ethidium bromide staining. 
RESULTS
Dose-response curves of Ad-p53 and Ad-LacZ
We initially examined the dose-response effects of Adp53 or Ad-LacZ on the cytotoxicity of two human lung cancer cell lines differing in their p53 status. Null-p53-expressing H1299 and wt-p53-containing H460 were selected as representative cell lines of the absence and presence of endogenous wt-p53, respectively. 5-bromo-4-chloro-3-indolyl ␤-D-galactoside staining of Ad-LacZinfected cancer cells showed highly efficient infectivity, and Western blot analysis revealed a dose-dependent expression after infection of Ad-p53 (data not shown).
IC 50 values of Ad-p53 and Ad-LacZ in H1299 were and Ad-LacZ (B) in combination with DNA-damaging agents (CDDP, etoposide, and SN-38) against H1299 and H460. On the basis of the dose-response curve for an adenovirus and an anti-cancer agent, the three isoeffect lines of drug combinations (mode I, mode IIa, and mode IIb) were drawn as described in Materials and Methods. The maximum area surrounded by the two isoeffect lines was defined as the envelope of additivity. Because each data point plotted from the combination experiment of Ad-p53 and DNA-damaging agents fell in the inner space of the envelope of additivity, the interactions were considered to be synergistic. In contrast, the combined effects of AdLacZ with DNA-damaging agents were additive, because each data point fell within the space of the envelope. The parameters on both axes indicate the drug concentrations relative to their IC 50 values (IC 50 units). obtained at MOIs of 9.4 Ϯ 0.5 and 74.0 Ϯ 4.3, respectively (Fig 1) . This suggested that Ad-p53 was more cytotoxic than Ad-LacZ in H1299 cells, consistent with a p53 specific effect. In contrast, the IC 50 values of Ad-p53 and Ad-LacZ against H460 were similar (MOIs of 493 Ϯ 5.0 and 520 Ϯ 7.0, respectively). Thus, compared with H1299 cells, H460 cells appeared to be more resistant to Ad-p53-induced cytotoxicity.
Isobologram analyses of Ad-p53 and Ad-LacZ in combination with anti-cancer agents
To assess whether Ad-p53 enhances the chemosensitivity of H1299 and H460 cells in combination with differing anti-cancer agents, we tested DNA-damaging agents (CDDP, etoposide, and SN-38) and antitubulin agents (paclitaxel and docetaxel). Cytotoxicity was measured by MTT assay, and any combined effects on IC 50 values were analyzed by isobolograms. The IC 50 values of these agents against H1299 and H460 are shown in Table 1 .
In both H1299 and H460 cells, simultaneous exposure to Ad-p53 and DNA-damaging agents led to a synergistic effect between the two agents (Fig 2A) . In contrast, Ad-p53 combined with antitubulin agents showed only additive effects in both cell lines (Fig 3) . As expected, control Ad-LacZ only revealed additive effects with all five anti-cancer agents in these cell lines (Fig 2B and  data not shown) .
As the synergistic effect of Ad-p53 with DNA-damaging agents was seen in wt-p53 (H460) and null-p53 (H1299) cells, we considered the possibility that this effect may be independent of intrinsic tumor p53 status. To confirm this, we investigated the combined effects of Ad-p53 with DNA-damaging agents in five additional NSCLC cell lines with various p53 statuses. The five cell lines used were H358 (null-p53), A549 (wt-p53), and H23, H226, and H322 (point mutations). The detailed p53 statuses 20, 21 and IC 50 values of adenoviruses and anti-cancer agents in these cell lines are summarized in Table 1 .
Like H1299 and H460, isobolograms showed synergistic effects of Ad-p53 in combination with DNA-damaging agents in H358, A549, H226, and H322 cells (Fig 4A  and data not shown) . In H23 cells with a p53 codon 246 (246 IIe ) missense mutation, Ad-p53 and Ad-LacZ had additive effects with DNA-damaging agents (Fig 4B and  data not shown) . In addition, we assessed the combined effects of Ad-p53 with antitubulin agents on the H23 and H322 cell lines. As expected, additive effects were observed in both cell lines (data not shown).
Because 246 IIe mt-p53 has been reported to behave in a dominant-negative fashion according to a yeast-based assay, 22 a Western blot analysis was performed to examine whether the transcriptional activity of exogenous wt-p53 is inhibited by endogenous mt-p53. After H23 cells were infected with Ad-p53, a dose-dependent increase in p53 expression and induction of the downstream p21 gene product were observed (Fig 4C) , suggesting that 246
IIe mt-p53 may not strongly suppress wt-p53 in H23 cells, or that the dominant-negative activity of the mt-p53 may simply be extinguished by more abundant exogenous wt-p53. Collectively, our results indicate that Ad-p53 in simultaneous administration with a DNA-damaging agent might synergistically enhance the chemosensitivity of the majority of NSCLCs independently of their intrinsic p53 status.
Ad-p53 enhances apoptosis induced by DNAdamaging agents
To determine whether the synergistic interaction of Ad-p53 with DNA-damaging agents was due to stimulation of the apoptotic response induced by anti-cancer agents, we examined the effect of a sublethal dose of Ad-p53 on seven cell lines that were simultaneously exposed to SN-38 by flow cytometry. Each cell line was mock-infected or infected with Ad-p53 or Ad-LacZ and simultaneously treated or untreated with SN-38. At 3 days posttreatment, cells were harvested, stained with propidium iodide, and assayed for DNA content. Representative data on cell-cycle profiles are shown in Figure 5 .
Under the condition that A549 cells were infected with 20 MOIs of Ad-p53, which was sublethal to the cells, simultaneous exposure to 1 nM of SN-38 led to a significant increase in the subdiploid population compared with SN-38 alone or SN-38 with the same MOI of Ad-LacZ (P Ͻ .05), suggesting that exogenous wt-p53 augmented the apoptosis induced by SN-38. The augmentation of apoptosis by Ad-p53 was also seen in the H1299, H460, H226, H322, and H358 cell lines as well as with CDDP and etoposide (Fig 5 and data not shown) . In contrast, there was no significant difference in the subdiploid population in mock-infected, Ad-p53-infected, or Ad-LacZ-infected H23 cells that were cotreated with SN-38 (Fig 5) . In addition, Ad-p53 did not enhance the apoptotic response induced by paclitaxel in four of the cell lines (H23, H322, H460, and H1299) examined (data not shown).
To confirm the finding that Ad-p53 could enhance the apoptotic response induced by SN-38, DNAs were isolated from mock-infected, Ad-p53-infected, or AdLacZ-infected cancer cells treated with or without SN-38 and electrophoresed for DNA ladder formation. In the H460 and H322 cell lines, a sublethal dose of Ad-p53 administered with SN-38 clearly enhanced low-molecu- H23 (B) . The combined effects of Ad-p53 on the chemosensitivity of H322 cells were synergistic; however, these effects were additive on the chemosensitivity of H23 cells. C: Western blot analyses of p53 and p21 in H23 cells after Ad-p53 infection. H23 has a missense p53 mutation at codon 246 (246 IIe ). A dose-dependent increase in the expression of p53 and p21 was observed, suggesting that 246
IIe mt-p53 may not strongly behave in a dominant-negative fashion to transcript target genes. lar weight DNA fragmentation compared with SN-38 alone or SN-38 with Ad-LacZ (Fig 6) . We also observed an augmentation of low-molecular weight DNA formation by Ad-p53 in all of the cell lines except H23 cells (data not shown). Taking these findings into consideration, the synergistic interaction between Ad-p53 and DNA-damaging agents may be attributed to the enhancement of apoptosis by exogenous wt-p53.
DISCUSSION
In this study, we addressed the ability of exogenous wt-p53 to modulate chemosensitivity to five anti-cancer agents that have been used frequently in the treatment of NSCLC patients. In addition, Ad-p53 in combination with DNA-damaging agents synergistically enhanced the chemosensitivity against six of seven NSCLC cell lines with various p53 statuses. A possible explanation for this synergistic enhancement is that, after exposure to Adp53 and a DNA-damaging agent, DNA damage stimulated quantitative and qualitative changes of exogenous wt-p53 through rapid accumulation and modulation in cancer cells. This may then lead to superinduction of p53-dependent apoptosis above and beyond the cell death induced by Ad-p53 and a DNA-damaging agent independently. Although further investigation is required to validate this hypothesis, there are data dem- A549 and H1299 cells exposed to both SN-38 and a sublethal dose of Ad-p53 for 72 hours showed a significant increase in the subdiploid cell population compared with cells treated with SN-38 alone or SN-38 with Ad-LacZ (P Ͻ .05 by Student's t test). In contrast, no significant difference in subdiploid population was observed in SN-38-treated H23 cells, which were uninfected or infected with Ad-p53 or Ad-LacZ.
onstrating that DNA damage stimulated p53 activity by stabilization and modulation, leading to an induction of apoptosis. 23, 24 Conversely, Ad-p53 only had additive effects with antitubulin agents, suggesting that the synergism between Ad-p53 and anti-cancer drugs appeared to be specific to DNA-damaging agents, which tend to involve p53 pathways. This notion that perhaps p53 pathways may not be crucial to the action of antitubulin agents is supported by the apparent lack of in vivo association between the p53 status of cancer cells and the paclitaxel response. 25 In H23 cells with 246
IIe mt-p53, which was reported to behave in a dominant-negative fashion according to a yeast-based assay, 22 Ad-p53 did not confer increased chemosensitivity to DNA-damaging agents. The lack of synergistic enhancement of chemosensitivity may be explained by the dominant-negative effect of endogenous mt-p53. However, this possibility is less likely, because the endogenous transcriptional target p21 was transactivated in H23 cells after infection with Ad-p53. Another possible explanation is that genetic or epigenetic alterations of the other regulatory genes acting as either upstream or downstream components in the p53 signaling cascade might abrogate the execution of p53-dependent apoptosis. We are testing the lack of response in H23 cells further, as it may lead to a new understanding of the mechanisms of the p53-dependent apoptotic pathway.
Our finding that synergy between Ad-p53 and DNAdamaging agents was observed in six of seven NSCLC cell lines with different p53 mutations suggests that their synergistic interactions may be independent of endogenous p53 status. Our results extend and confirm the results from a study showing increased chemosensitivity to DNA-damaging agents after introduction of wt-p53 in cancer cells regardless of their p53 status. 26 These findings may ultimately lead to improvement in human lung cancer therapy, because two or more agents with synergistic interaction have been used as a rationale for their inclusion in clinical protocols. 19 Although Ad-p53 may cause enhanced damage to normal tissues in vivo in combination with DNA-damaging agents, enhanced toxicities against normal tissues adjacent to or within tumor have not been observed during the course of local Ad-p53 treatment combined with systemic CDDP administration in lung cancer patients.
14 Thus, exogenously overexpressed p53 in combination with DNA-damaging agents might increase cellular susceptibility to apoptosis specifically against tumor cells. Although additional in vivo experiments are needed, the knowledge that Ad-p53 sensitizes the majority of NSCLC cells to DNA-damag- ing agents may provide a foundation for new therapeutic approaches such as gene therapy and pharmacological modulation of p53 protein.
